<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: Potentially modifiable biomarkers may influence the decline in estimated GFR (eGFR), but few data are currently available in type 2 diabetic adults </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: We studied 516 women with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> in the Nurses' Health Study with data on <z:chebi fb="23" ids="18059">lipid</z:chebi> and inflammatory biomarkers from plasma collected in 1989 and plasma <z:chebi fb="0" ids="16737">creatinine</z:chebi> in samples collected in 1989 and 2000 </plain></SENT>
<SENT sid="2" pm="."><plain>An estimated GFR decline of &gt;or=25% over 11 years was the outcome of interest </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Comparing the highest with the lowest quartile, soluble <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor receptor 2 (sTNFR-2) was independently associated with an eGFR decline of &gt;or=25% (multivariate OR 5.81; 95% CI 2.90-11.65); this association was stronger in <z:mp ids='MP_0001261'>obese</z:mp> women (OR 16.76; 95% CI 4.69-59.90 for BMI &gt;or=30 kg/m(2); OR 2.78, 95% CI 1.12-6.89 for BMI &lt;30 kg/m(2); p for interaction = 0.02) </plain></SENT>
<SENT sid="4" pm="."><plain>No <z:chebi fb="23" ids="18059">lipids</z:chebi> (total cholesterol, <z:chebi fb="1" ids="47774">LDL-cholesterol</z:chebi>, <z:chebi fb="4" ids="47775">HDL-cholesterol</z:chebi>, non-<z:chebi fb="4" ids="47775">HDL-cholesterol</z:chebi>, <z:chebi fb="0" ids="17855">triacylglycerols</z:chebi>, <z:chebi fb="1" ids="6495">lipoprotein</z:chebi>(a), or <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> B) or other markers of <z:mp ids='MP_0001845'>inflammation</z:mp> (C-reactive protein, fibrinogen, E-selectin, intracellular cell <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule 1, leptin or adiponectin) were significantly associated with eGFR decline after multivariable adjustment </plain></SENT>
<SENT sid="5" pm="."><plain>CONCLUSIONS/INTERPRETATION: Elevated sTNFR-2 levels may be an important and potentially modifiable risk factor for eGFR decline in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, especially in those with a BMI of &gt;or=30 kg/m(2) </plain></SENT>
</text></document>